- Home
- CSPI vs AARD Comparison
CSPI vs AARD Comparison
Compare CSPI & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CSPI
- AARD
- Stock Information
- Founded
- CSPI 1968
- AARD 2017
- Country
- CSPI United States
- AARD United States
- Employees
- CSPI N/A
- AARD N/A
- Industry
- CSPI EDP Services
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- CSPI Technology
- AARD Health Care
- Exchange
- CSPI Nasdaq
- AARD Nasdaq
- Market Cap
- CSPI 146.9M
- AARD 154.9M
- IPO Year
- CSPI 1987
- AARD 2025
- Fundamental
- Price
- CSPI $16.49
- AARD $7.37
- Analyst Decision
- CSPI
- AARD Strong Buy
- Analyst Count
- CSPI 0
- AARD 4
- Target Price
- CSPI N/A
- AARD $31.50
- AVG Volume (30 Days)
- CSPI 18.3K
- AARD 130.3K
- Earning Date
- CSPI 05-07-2025
- AARD 01-01-0001
- Dividend Yield
- CSPI 0.75%
- AARD N/A
- EPS Growth
- CSPI N/A
- AARD N/A
- EPS
- CSPI 0.02
- AARD N/A
- Revenue
- CSPI $55,514,000.00
- AARD N/A
- Revenue This Year
- CSPI N/A
- AARD N/A
- Revenue Next Year
- CSPI N/A
- AARD N/A
- P/E Ratio
- CSPI $855.59
- AARD N/A
- Revenue Growth
- CSPI N/A
- AARD N/A
- 52 Week Low
- CSPI $10.76
- AARD $4.88
- 52 Week High
- CSPI $21.95
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- CSPI 54.40
- AARD N/A
- Support Level
- CSPI $14.40
- AARD N/A
- Resistance Level
- CSPI $16.09
- AARD N/A
- Average True Range (ATR)
- CSPI 1.00
- AARD 0.00
- MACD
- CSPI 0.21
- AARD 0.00
- Stochastic Oscillator
- CSPI 97.88
- AARD 0.00
About CSPI CSP Inc.
CSP Inc along with its subsidiaries develops and markets IT integration solutions, security products, managed IT services, cloud services, purpose-built network adapters, and high-performance cluster computer systems. The firm operates in two segments namely Technology Solutions, where the company focus on value-added reseller integrated solutions including third-party hardware, software, and technical computer-related consulting, and High-Performance Products segments, where the company design, manufacture and deliver products and services to customers that require specialized cyber security services, networking and signal processing. It generates a majority of its revenue from the Technology Solutions segment. Geographically, the company generates its maximum revenue from the Americas.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.